CD200 and acute myeloid leukemia: Although AML-MRC has been reported to include a worse outcome by comparison to AML-NOS [5], especially in patients carrying a mutated ASXL1 gene [31], Devillier et al. pointed out the heterogeneity of AML-MRC, in which those with intermediate cytogenetic risk had non-inferior survival in patients with AML-NOS [32].